Ketamine Clinical Trials: The Evidence Behind the Treatment

Ketamine's journey from surgical anesthetic to psychiatric breakthrough is built on a foundation of rigorous clinical research spanning more than two decades. This page provides a comprehensive overview of the landmark clinical trials, pivotal studies, and ongoing research that form the evidence base for ketamine therapy.

Whether you are a patient evaluating treatment options, a clinician assessing the evidence, or simply curious about the science, this guide covers every major study that has shaped how ketamine is used to treat depression, PTSD, chronic pain, and other conditions.

The Discovery: How a Surgical Drug Became an Antidepressant

The Berman Study (2000) -- The First Hint

The story begins in 2000, when Dr. Robert Berman and colleagues at Yale University published the first study demonstrating ketamine's antidepressant potential. In this small proof-of-concept trial, seven patients with major depression received a single sub-anesthetic dose of IV ketamine (0.5 mg/kg over 40 minutes).^[1]

The results were striking: four of the seven patients showed a significant reduction in depressive symptoms within 72 hours -- a timeline unheard of in psychiatry, where standard antidepressants typically take 4-6 weeks to show effects. Though the sample size was too small for definitive conclusions, the study opened a door that would transform the field.

The Zarate Study (2006) -- The Landmark Trial

The study that electrified the psychiatric community was published in 2006 by Dr. Carlos Zarate Jr. and his team at the National Institute of Mental Health (NIMH). This was the first double-blind, randomized, placebo-controlled crossover trial of ketamine for treatment-resistant depression (TRD).^[2]

Study design:

• 18 patients with treatment-resistant depression
• Each patient received both a single IV ketamine infusion (0.5 mg/kg over 40 minutes) and a saline placebo, separated by a washout period
• Crossover design: every patient served as their own control
• Primary outcome: Hamilton Depression Rating Scale (HDRS) at 24 hours

Key findings:

• 71% of patients met response criteria (50%+ reduction in HDRS) within 24 hours of ketamine infusion
• 29% achieved full remission within 24 hours
• 0% of patients responded to placebo within 24 hours
• The onset of action was within 2 hours -- unprecedented for any antidepressant
• Effects lasted approximately 1-2 weeks in most responders

Why it mattered: This study demonstrated three revolutionary findings: (1) depression could be treated rapidly, not over weeks; (2) a medication acting on the glutamate system (not serotonin) could treat depression; and (3) patients who had failed multiple conventional treatments could still respond. It launched the field of rapid-acting antidepressants.

Confirmation and Expansion (2010-2016)

The Murrough Trial (2013) -- Multi-Site Confirmation

While the Zarate study was groundbreaking, it was a small, single-site trial. The field needed replication at scale. In 2013, Dr. James Murrough and colleagues published the largest randomized controlled trial of IV ketamine for TRD at that time.^[3]

Study design:

• 73 patients with treatment-resistant depression
• Two sites (Mount Sinai and Baylor)
• Randomized to IV ketamine (0.5 mg/kg over 40 minutes) or midazolam (active placebo)
• Midazolam was chosen as an active control because it produces sedation, helping maintain the blind

Key findings:

• 64% response rate with ketamine vs. 28% with midazolam at 24 hours
• Statistically significant superiority of ketamine (odds ratio 2.18)
• Effects peaked at 24 hours and remained significant at 7 days
• No serious adverse events

Why it mattered: Multi-site confirmation with an active placebo control strengthened the evidence that ketamine's effects were not simply due to the sedating or dissociative experience, but to specific neurobiological mechanisms.

The Singh Dose-Frequency Study (2016)

As individual studies confirmed ketamine's efficacy, the critical question became: what is the optimal dosing schedule? Dr. Jaskaran Singh and colleagues at Janssen Research addressed this with a dose-frequency study.^[5]

Study design:

• 67 patients with treatment-resistant depression
• Randomized to twice-weekly or thrice-weekly IV ketamine (0.5 mg/kg) vs. placebo
• 4-week treatment period with 15-day follow-up

Key findings:

• Both twice-weekly and thrice-weekly ketamine were significantly superior to placebo
• Thrice-weekly dosing did not show additional benefit over twice-weekly
• Response rates: ~65% for both ketamine groups vs. ~12% for placebo
• The twice-weekly regimen became the standard of care for the initial series

Repeated Dosing Studies (2010-2016)

Several studies examined what happens with repeated ketamine infusions -- the protocol now used clinically:

Aan het Rot et al. (2010) -- Six infusions over 12 days in 10 patients with TRD. Nine of 10 patients responded, and effects were maintained through the treatment period. This was among the first demonstrations that repeated dosing could sustain benefits.

Phillips et al. (2019) -- Compared single infusion, repeated infusions (3x/week for 2 weeks), and maintenance infusions. Repeated infusions produced more sustained remission, and maintenance infusions prevented relapse. The median time to relapse without maintenance was 18 days.^[14]

The FDA Approves Esketamine: TRANSFORM and SUSTAIN Trials (2017-2019)

Understanding Esketamine vs. Ketamine

Ketamine is a racemic mixture -- it contains two mirror-image molecules (enantiomers): S-ketamine (esketamine) and R-ketamine. Janssen Pharmaceuticals developed intranasal esketamine (brand name Spravato) as a patentable pharmaceutical product. This allowed for the rigorous Phase 2 and Phase 3 clinical trial program required for FDA approval.

TRANSFORM Trials (Phase 3)

Three pivotal Phase 3 studies formed the basis for FDA approval:

TRANSFORM-1 (Daly et al., 2018):^[6]

• 346 patients with treatment-resistant depression
• Fixed doses of esketamine nasal spray (28 mg, 56 mg, or 84 mg) plus new oral antidepressant vs. placebo nasal spray plus new oral antidepressant
• The 56 mg and 84 mg doses showed statistically significant improvement in depression scores at 4 weeks

TRANSFORM-2 (Popova et al., 2019):^[7]

• 223 patients with treatment-resistant depression
• Flexible dosing (56 mg or 84 mg) of esketamine plus new oral antidepressant vs. placebo plus new oral antidepressant
• Statistically significant improvement in depression scores at 4 weeks (primary endpoint)
• Response rate: 69.3% for esketamine vs. 52.0% for placebo

TRANSFORM-3:

• Focused on older adults (65+) with treatment-resistant depression
• Did not meet its primary endpoint (not statistically significant)
• Still showed clinically meaningful trends in favor of esketamine

SUSTAIN Trials (Relapse Prevention)

SUSTAIN-1 (Daly et al., 2019):^[8]

• 297 patients who had achieved remission or stable response on esketamine
• Randomized to continue esketamine or switch to placebo nasal spray (both groups continued oral antidepressants)
• Patients who continued esketamine had a significantly lower relapse rate (26.7%) compared to those switched to placebo (45.3% for remitters, 57.6% for responders)

Why it mattered: This study demonstrated that esketamine was not just producing temporary relief -- continued treatment actively prevented relapse. It also provided the evidence for the maintenance phase of treatment.

FDA Approval

Based primarily on TRANSFORM-2, SUSTAIN-1, and supporting data, the FDA approved Spravato (esketamine nasal spray) in March 2019 for treatment-resistant depression. This was the first genuinely new mechanism of action approved for depression since the introduction of SSRIs in the late 1980s.

In August 2020, the FDA expanded the approval to include major depressive disorder with acute suicidal ideation or behavior, based on the ASPIRE trials.

Ketamine for Suicidality: The ASPIRE Trials (2020-2021)

One of the most significant areas of ketamine research is its rapid anti-suicidal effects -- a property unique among psychiatric medications.

The Wilkinson Meta-Analysis (2018)

Before the ASPIRE trials, a systematic review and individual participant data meta-analysis by Wilkinson et al. pooled data from 10 studies examining ketamine's effects on suicidal ideation.^[11]

Findings:

• A single dose of ketamine significantly reduced suicidal ideation within 24 hours
• The anti-suicidal effect was partially independent of the antidepressant effect -- meaning ketamine reduces suicidal thoughts even in patients whose depression does not fully respond
• Effects on suicidality were evident as early as 4 hours post-infusion

ASPIRE-1 and ASPIRE-2 (2020-2021)

These Phase 3 trials specifically studied esketamine for patients in psychiatric crisis -- those with major depression and active suicidal ideation with intent.^[9][10]

ASPIRE-1 (Fu et al., 2020):

• 226 patients presenting to emergency departments or psychiatric units with active suicidal ideation
• Esketamine 84 mg nasal spray plus comprehensive standard of care vs. placebo plus standard of care
• Significant improvement in depression scores at 24 hours favoring esketamine

ASPIRE-2 (Ionescu et al., 2021):

• 230 patients with the same acute suicidal presentation
• Confirmed the rapid antidepressant effect in this high-risk population
• Both studies showed numerical (though not always statistically significant) reductions in suicidality measures

Why they mattered: These trials led to the expanded FDA indication for Spravato in acutely suicidal patients, providing the first rapid-acting pharmacological treatment specifically studied in this population.

Ketamine vs. ECT: The ELEKT-D Trial (2023)

For decades, electroconvulsive therapy (ECT) has been the gold standard for severe treatment-resistant depression. In 2023, the ELEKT-D trial published in the New England Journal of Medicine directly compared the two treatments.^[12]

Study design:

• 403 patients with treatment-resistant depression
• Randomized to IV ketamine (0.5 mg/kg, twice weekly for 3 weeks) or ECT (thrice weekly for 3 weeks)
• Non-inferiority design

Key findings:

• Ketamine was non-inferior to ECT (response rates: 55.4% for ketamine vs. 41.2% for ECT)
• Ketamine actually showed higher response rates, though the study was designed for non-inferiority, not superiority
• ECT was associated with significantly more cognitive side effects (memory impairment, confusion)
• Ketamine was better tolerated overall

Why it mattered: This landmark trial positioned ketamine as a viable alternative to ECT for many patients, potentially sparing them the cognitive side effects and anesthesia requirements of ECT while achieving comparable or better outcomes.

Ketamine for PTSD: Key Evidence

Feder et al. (2014) -- The Landmark PTSD Trial

The most cited ketamine-PTSD study was published by Dr. Adriana Feder and colleagues.^[4]

Study design:

• 41 patients with chronic PTSD
• Randomized crossover: IV ketamine (0.5 mg/kg) vs. midazolam (active placebo)
• Primary outcome: Impact of Event Scale-Revised (IES-R) at 24 hours

Key findings:

• Ketamine produced significant reductions in PTSD symptom severity at 24 hours
• Effects were evident across all PTSD symptom clusters (re-experiencing, avoidance, hyperarousal)
• Response to ketamine was associated with changes in functional connectivity of brain regions involved in fear processing

Subsequent PTSD Research

Multiple subsequent studies have confirmed ketamine's efficacy for PTSD, and the combination of ketamine with psychotherapy (KAP -- ketamine-assisted psychotherapy) for trauma processing is an active and promising area of investigation.

Ketamine for Chronic Pain

Consensus Guidelines (2018)

The American Society of Regional Anesthesia and Pain Medicine (ASRA) published consensus guidelines on IV ketamine for acute and chronic pain management.^[15]

Key recommendations:

• Strong evidence supports ketamine for CRPS (complex regional pain syndrome)
• Moderate evidence for neuropathic pain, fibromyalgia, and cancer pain
• Doses for pain are typically higher than for depression (0.5-1.0 mg/kg/hour for 2-4 hours)
• Multi-day infusion protocols may be necessary for chronic pain

Racemic Ketamine vs. Esketamine: Comparative Evidence

A critical question in the field is whether racemic ketamine (the standard IV formulation containing both S- and R-enantiomers) is more or less effective than esketamine alone.

Bahji Meta-Analysis (2021)

A systematic review and meta-analysis by Bahji et al. compared the two formulations.^[13]

Findings:

• Racemic IV ketamine showed higher response rates than intranasal esketamine
• However, the comparison is confounded by different delivery routes (IV vs. nasal), which have different bioavailability
• Both formulations were significantly superior to placebo
• The R-enantiomer of ketamine may contribute additional therapeutic effects through different mechanisms

Clinical implications: Many experts believe racemic IV ketamine may be more effective than esketamine, but the evidence is not conclusive due to confounding factors. The choice often comes down to practical considerations: insurance coverage favors Spravato, while clinical flexibility and potentially greater efficacy favor IV ketamine.

The Future: Ongoing Research and Novel Approaches

Ketamine Metabolites (Hydroxynorketamine)

One of the most exciting areas of current research involves hydroxynorketamine (HNK), a metabolite of ketamine. A groundbreaking 2016 study in Nature by Zanos et al. found that HNK produced antidepressant effects in mice without the dissociative properties of ketamine.^[16]

If HNK-based treatments prove effective in humans, they could provide ketamine's antidepressant benefits without requiring clinic-based administration or producing dissociation -- potentially making the treatment accessible to far more patients.

Biomarker Research

Researchers are actively seeking biomarkers that predict who will respond to ketamine:

• Neuroimaging studies using fMRI have identified patterns of brain connectivity that correlate with ketamine response
• Blood biomarkers including BDNF levels, inflammatory markers, and metabolomics profiles are under investigation
• Genetic studies are exploring whether specific gene variants (particularly in glutamate receptor genes) predict response
• EEG markers may offer a practical, clinic-based tool for predicting and monitoring treatment response

Combination Therapies

Active trials are exploring ketamine combined with:

• Psychotherapy (KAP) -- leveraging the neuroplasticity window for enhanced therapeutic work
• Transcranial magnetic stimulation (TMS) -- dual neuromodulation approaches
• Novel antidepressants -- including psilocybin and MDMA in sequential protocols
• Cognitive training -- using the plasticity window for targeted cognitive interventions

Extended-Release Formulations

Several pharmaceutical companies are developing oral extended-release ketamine formulations that could provide more convenient, at-home dosing with more predictable blood levels than current sublingual formulations.

Summary: The Evidence at a Glance

The clinical evidence for ketamine therapy has grown from a single small trial in 2000 to one of the most robust bodies of research in modern psychiatry. While questions remain about optimal dosing, long-term outcomes, and patient selection, the fundamental finding -- that depression can be treated rapidly through glutamatergic mechanisms -- represents one of the most significant advances in mental health treatment in decades.

For a deeper understanding of the science behind these findings, read about the mechanism of action. For practical information on safety, see our safety profile.